A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
NCT06079346 · STOP-PC Phase 2/3Recruiting
- Lead sponsor
- Oncotelic Inc. (Industry)
- Enrollment
- 455 (estimated)
- Start date
- 1 May 2024
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 1 Jun 2027
- Last update posted
- 13 Aug 2024
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- OT-101 Drug
- mFOLFIRINOX Drug
Conditions and primary outcome
- Pancreatic Ductal Adenocarcinoma
Primary outcome
Overall Survival (OS) (2.5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06079346.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06079346 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.